Lista de obras -

A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD

artículo científico publicado en 2020

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

artículo científico publicado en 2009

Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death

artículo científico publicado en 2010

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

artículo científico publicado en 2013

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

article

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

artículo científico publicado en 2013

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

artículo científico publicado en 2016

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

artículo científico publicado en 2015

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial

artículo científico publicado en 2017

Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings

artículo científico publicado en 2012

Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials

artículo científico publicado en 2012

Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology

artículo científico publicado en 2012

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial

artículo científico publicado en 2017

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

article

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

article

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

article

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

artículo científico publicado en 2015

Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).

artículo científico publicado en 2012

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

artículo científico publicado en 2013

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

article

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

scientific article published on 19 December 2018

Lista de obras de

A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial

Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings

Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials

Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST).

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)